The road toward developing a non-Hodgkin's lymphoma vaccine is littered with failures. Two companies, Genitope and Favrille, had trials fail in 2007 and 2008 and then quickly closed down shop. The challenges were writ large again last week when Biovest filed for bankruptcy--for the second time in 5 years.
Biovest International's stock has risen by 15% on two pieces of news about its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, BiovaxID.
Biovest has chosen Canada for the first submission for approval of its personalized cancer vaccine, BiovaxID. The vaccine could become the first cancer vaccine marketed for lymphoma patients.
In a study published in the online version of the Journal of Clinical Oncology, researchers at the University of Texas MD Anderson Cancer Center say a Phase III trial of the therapeutic vaccine
Two years ago, Biovest and parent company Accentia entered into bankruptcy protection after stumbling under the heavy weight of debt just as the credit crisis was hitting with full force. As the
The European Medicines Agency has designated Biovest International's BiovaxID vaccine as an orphan medicinal product for mantle cell lymphoma. The personalized cancer vaccine has received orphan drug
Biovest International has announced that the FDA has granted orphan drug designation to BiovaxID, its personalized cancer vaccine, for a second lymphoma indication. "With promising clinical trials